关于阵发性心房纤颤是否需要抗凝治疗的思考

阵发性心房纤颤与持续性心房纤颤同样面临着缺血性脑卒中风险，而关于阵发性房颤是否需要华法林抗凝治疗是目前争论热点问题。阵发性房颤是否抗凝治疗使患者面临着严重出血或血栓栓塞风险。循证医学论证了阵发性房颤抗凝治疗必要性及风险性，并且由于阵发性房颤患者有着不同的脑卒中及出血风险，个体差异的绝对性和多样性客观上要求对患者进行风险／效益比评估，在循证医学基础上进行个体化治疗。

Thought of Anticoagulant Therapy on Paroxysmal Atrial Fibrillation

The risk of ischemic stoke in patients with paroxysmal atrial fibrillation（PAF）, as well as patients with persistent atrial fibrillation, increased significantly. At present, whether patients with PAF need Warfarin anticoagulant therapy was a hot topic. Whether choosing anticoagulant therapy or not,patients with PAF faced the risk between severe hemorrhage and thromboembolism. Evidence--based medical records showed that there were both necessity to prevent cerebral apoplexy and risk of hemorrhage by adopting anticoagulant therapy on PAF patients. The individual difference on the opposite tendency made it necessary to evaluate the risk--benefit radio of patients with PAF and to work out customized therapy plan based on population--based cohort.